Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2023; 12(02): 104-111
DOI: 10.1055/s-0043-1761942
Original Article
Breast Cancer

A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India

Puneet Kaur Somal 
1   Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Sankalp Sancheti 
1   Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Aishwarya Sharma
1   Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Akash Pramod Sali
1   Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Debashish Chaudhary 
2   Department of Surgical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Alok Goel
3   Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Tapas Kumar Dora 
4   Department of Radiotherapy, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Rahat Brar 
5   Department of Radio-diagnosis, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Ashish Gulia 
6   Department of Surgical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
,
Jigeeshu Divatia
7   Department of Anesthesiology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Zoom Image
Puneet Kaur Somal

Objective Classification of breast cancer into different molecular subtypes has important prognostic and therapeutic implications. The immunohistochemistry surrogate classification has been advocated for this purpose. The primary objective of the present study was to assess the prevalence of the different molecular subtypes of invasive breast carcinoma and study the clinicopathological parameters in a tertiary care cancer center in rural North India.

Materials and Methods All female patients diagnosed with invasive breast cancer and registered between January 1, 2015, and December 31, 2020, were included. Patients with bilateral cancer, missing information on HER2/ER/PR receptor status, absence of reflex FISH testing after an equivocal score on Her 2 IHC were excluded. The tumors were classified into different molecular subtypes based on IHC expression as follows-luminal A-like (ER- and PR-positive, Her2-negative, Ki67 < 20%), luminal B-like Her2-negative (ER-positive, Her2-negative and any one of the following Ki67% ≥ 20% or PR-negative/low, luminal B-like Her2-positive (ER- and HER2-positive, any Ki67, any PR), Her2-positive (ER- and PR-negative, Her2-positive) and TNBC (ER, PR, Her2-negative). Chi square test was used to compare the clinicopathological parameters between these subtypes.

Results A total of 1,625 cases were included. Luminal B-like subtype was the most common (41.72%). The proportion of each subtype was luminal A (15.69%), luminal B Her2-negative (23.93%), luminal B Her2-positive (17.78%), Her2-positive (15.26%), TNBC (27.32%). Majority of the tumors were Grade 3 (75.81%). Nodal metastases were present in 59%. On subanalysis of the luminal type tumors without Her2 expression (luminal A-like and luminal B-like (Her2-negative), luminal A-like tumors presented significantly with a lower grade (p < 0.001) and more frequent node-negative disease in comparison to luminal B-like (Her2-negative) tumors. In comparison to other subtypes, TNBC tumors were more frequently seen in the premenopausal age group (p < 0.001) and presented with node-negative disease (p < 0.001).

Conclusion This is one of the largest studies that enumerates the prevalence of various molecular subtypes of breast cancer in North India. Luminal B-like tumors were the most common followed by TNBC. TNBC tumors presented more commonly in premenopausal age group and with node negative disease in comparison to other subtypes.

Keywords

molecular subtypes - breast cancer - India - immunohistochemical surrogates - TNBC


Publication History

Article published online:
09 March 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 2 Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 2017; 13 (04) 289-295
    CrossrefPubMedGoogle Scholar
  • 3 Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 2013; 133 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 4 Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol 2020; 27 (01) 27-35
    CrossrefPubMedGoogle Scholar
  • 5 Habashy HO, Powe DG, Abdel-Fatah TM. et al. A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. Histopathology 2012; 60 (06) 854-863
    CrossrefPubMedGoogle Scholar
  • 6 Rakha EA, Green AR. Molecular classification of breast cancer: what the pathologist needs to know. Pathology 2017; 49 (02) 111-119
    CrossrefPubMedGoogle Scholar
  • 7 Cheang MC, Chia SK, Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101 (10) 736-750
    CrossrefPubMedGoogle Scholar
  • 8 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22 (08) 1736-1747
    CrossrefPubMedGoogle Scholar
  • 9 Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update. Arch Pathol Lab Med 2016; 140 (08) 806-814
    CrossrefPubMedGoogle Scholar
  • 10 Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 2010; 6 (04) 195-197
    CrossrefPubMedGoogle Scholar
  • 11 Wolff AC, Hammond ME, Hicks DG. et al; American Society of Clinical Oncology, College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31 (31) 3997-4013
    CrossrefPubMedGoogle Scholar
  • 12 Dowsett M, Nielsen TO, A'Hern R. et al; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103 (22) 1656-1664
    CrossrefPubMedGoogle Scholar
  • 13 Goldhirsch A, Winer EP, Coates AS. et al; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24 (09) 2206-2223
    CrossrefPubMedGoogle Scholar
  • 14 Perou CM, Sørlie T, Eisen MB. et al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747-752
    CrossrefPubMedGoogle Scholar
  • 15 Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009; 7 (1-2): 4-13
    CrossrefPubMedGoogle Scholar
  • 16 Gogia A, Deo SV, Shukla NK, Mathur S, Sharma DN, Tiwari A. Clinicopathological profile of breast cancer: an institutional experience. Indian J Cancer 2018; 55 (03) 210-213
    CrossrefPubMedGoogle Scholar
  • 17 Verma S, Bal A, Joshi K, Arora S, Singh G. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India. APMIS 2012; 120 (12) 1008-1019
    CrossrefPubMedGoogle Scholar
  • 18 Doval DC, Sharma A, Sinha R. et al. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev 2015; 16 (12) 4959-4964
    CrossrefPubMedGoogle Scholar
  • 19 Shet T, Agrawal A, Nadkarni M. et al. Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is?. Indian J Pathol Microbiol 2009; 52 (02) 171-174
    CrossrefPubMedGoogle Scholar
  • 20 Sali AP, Sharma N, Verma A. et al. Identification of luminal subtypes of breast carcinoma using surrogate immunohistochemical markers and ascertaining their prognostic relevance. Clin Breast Cancer 2020; 20 (05) 382-389
    CrossrefPubMedGoogle Scholar
  • 21 Kunheri B, Raj RV, Vijaykumar DK, Pavithran K. Impact of St. Gallen surrogate classification for intrinsic breast cancer sub-types on disease features, recurrence, and survival in South Indian patients. Indian J Cancer 2020; 57 (01) 49-54
    CrossrefPubMedGoogle Scholar
  • 22 Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol 2014; 27 (04) 554-561
    CrossrefPubMedGoogle Scholar
  • 23 Batra A, Marwah N, Marwah S, Gupta S, Dharembra D, Sen RSt. Gallen's molecular subtypes in primary breast carcinoma in Indian population. Clin Cancer Investig J 2016; 5 (05) 416-423
    CrossrefGoogle Scholar
  • 24 Vasconcelos I, Hussainzada A, Berger S. et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. Breast 2016; 29: 181-185
    CrossrefPubMedGoogle Scholar
  • 25 Harish S, Anand S, Prashar M, Lohia N, Singh S, Viswanath S. Intrinsic subtyping of breast cancer and its relevance with clinicopathological features and outcomes in patients from North India: a single center experience. J NTR Univ Health Sci 2020; 9 (03) 164-171
    CrossrefGoogle Scholar
  • 26 Park S, Koo JS, Kim MS. et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012; 21 (01) 50-57
    CrossrefPubMedGoogle Scholar
  • 27 Prat A, Cheang MC, Martín M. et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013; 31 (02) 203-209
    CrossrefPubMedGoogle Scholar
  • 28 Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triple-negative breast cancer in India: systematic review and meta-analysis. J Glob Oncol 2016; 2 (06) 412-421
    CrossrefPubMedGoogle Scholar
  • 29 Lin NU, Vanderplas A, Hughes ME. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012; 118 (22) 5463-5472
    CrossrefPubMedGoogle Scholar
  • 30 Suhani, Parshad R, Kazi M, Seenu V, Mathur S, Dattagupta S, Haresh KP. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India. Indian J Cancer 2017; 54 (04) 658-663
    CrossrefPubMedGoogle Scholar
  • 31 Sharma M, Sharma JD, Sarma A. et al. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre. Asian Pac J Cancer Prev 2014; 15 (11) 4507-4511
    CrossrefPubMedGoogle Scholar